medric medric
[닫기]
잠시만 기다려 주세요. 로딩중입니다.

6-sialyllactose ameliorates dihydrotestosterone-induced benign prostatic hyperplasia through suppressing VEGF-mediated angiogenesis

BMB Reports 2019년 52권 9호 p.560 ~ 565
 ( Kim Eun-Yeong ) - Pusan National University School of Korean Medicine Department of Korean Medical Science

 ( Jin Bo-Ram ) - Sangji University College of Korean Medicine Department of Pharmacology
 ( Chung Tae-Wook ) - Pusan National University Korean Medicine Research Center for Healthy Aging
 ( Bae Sung-jin ) - Pusan National University Korean Medicine Research Center for Healthy Aging
 ( Park Hye-Rin ) - Pusan National University Korean Medicine Research Center for Healthy Aging
 ( Ryu Dong-Ryeol ) - Sungkyunkwan University School of Medicine Department of Molecular Cell Biology
 ( Jin Ling ) - Pusan National University School of Korean Medicine Department of Korean Medical Science
 ( An Hyo-Jin ) - Sangji University College of Korean Medicine Department of Pharmacology
 ( Ha Ki-Tae ) - Pusan National University School of Korean Medicine Department of Korean Medical Science

Abstract


Benign prostatic hyperplasia (BPH), a common disease in elderly males, is accompanied by non-malignant growth of prostate tissues, subsequently causing hypoxia and angiogenesis. Although VEGF-related angiogenesis is one of the therapeutic targets of prostate cancer, there is no previous study targeting angiogenesis for treatment of BPH. Dihydrotestosterone (DHT)- induced expressions of vascular endothelial growth factor (VEGF) in prostate epithelial RWPE-1 cells and human umbilical vascular endothelial cells (HUVECs). Conditioned media (CM) from DHT-treated RWPE-1 cells were transferred to HUVECs. Then, 6SL inhibited proliferation, VEGFR-2 activation, and tube formation of HUVECs transferred with CM from DHT-treated RWPE-1 cells. In the rat BPH model, 6SL reduced prostate weight, size, and thickness of the prostate tissue. Formation of vessels in prostatic tissues were also reduced with 6SL treatment. We found that 6SL has an ameliorative effect on in vitro and in vivo the BPH model via inhibition of VEGFR-2 activation and subsequent angiogenesis. These results suggest that 6SL might be a candidate for development of novel BPH drugs.

키워드

Benign prostatic hyperplasia; Dihydrotestosterone; VEGF; VEGFR-2; 6-Siallylactose
원문 및 링크아웃 정보
 
등재저널 정보